enatumab

Phase 2Monoclonal antibody

BBing Han

enatumab is one of 22 small molecule programs targeting Hemolytic Anemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemolytic AnemiaActive, not recruiting

Hemolytic AnemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Hemolytic Anemia

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Rituxan

2 3

Neoral

Novartis

Phase 3

1 4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Fostamatinib Bid

RRigel Pharmaceuticals

Phase 3

2 6

HMPL-523

HHutchison Medipharma Limited

Phase 3

1 7

Imbruvica

PPharmacyclics LLC.

Phase 2

2 8

Rayos

RRoxane Laboratories

Phase 2

1 9

Brukinsa

BBeOne Medicines

Phase 2

1 10

Ergamisol

WWim Janssens

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Hemolytic Anemia

NCT07190261

Clinical

Trials by Indication[1]

Hemolytic Anemia1 trial

A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

Not yet recruiting·BBing Han·Phase 2·NCT07190261·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for enatumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — enatumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for enatumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bing Han company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: BBing Han

enatumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hemolytic Anemia1 trial

References

Drug Info

Quick Facts

Related News